Shera Energy is making a preferential allotment of 45 lakh fully convertible warrants to promoters and two venture capital investors at an exercise price of ₹118, raising ₹53.1 crore. The warrants can be converted into equity shares within 18 months. After full conversion, promoter holding will rise to 66.82% from 62.35%, while public shareholding will fall to 33.18%. The fundraise has shareholder approval and in-principle clearance from the NSE, with the company stating it complies with SEBI and Companies Act requirements and disclosing no violations.

AKG Exim Ltd. promoter Kalapi Vinit Nagada pledged 38 lakh shares, or 11.96% of the company’s total equity, to ESAAR (India) on July 9, 2026. Before the pledge, he held 13.09% with no encumbrance; after the pledge, 1.13% of total equity remains unencumbered. The company reported a decline in operational income and net profit for FY2026.

Yasho Industries’ FY2025-26 annual report shows profit after tax of ₹2,526 lakhs, up 312.74% year on year, while revenue increased 22.85%. EBITDA rose 20.98%, and net profit margin improved to 3.04% from 0.90%. The company also secured a 15-year lubricant additives supply agreement with a global multinational, with customer advances of ₹51.40 Crore. It expects the contract to contribute annual revenue of around ₹150 Crore from FY2027-28 onward.

Ashwani Gulati, Kiran Gulati and Veerasha Trust have launched a mandatory open offer to acquire 26% of Jai Mata Glass at INR 1.85 per share. The offer follows their agreement to buy a 44.57% stake from the existing promoters for about INR 8244万, which would give the acquirers control of the company. Jai Mata Glass also said it has appointed Aashish Gupta as its new chief financial officer.

IVP Limited reported a 65% year-on-year rise in FY26 profit after tax to ₹1,868 Lakhs for the year ended March 31, 2026, alongside revenue from operations of ₹59,455 Lakhs and EBITDA of ₹3,852 Lakhs. The board recommended a final dividend of ₹1.5 per equity share of ₹10 each, with a total payout of ₹155 Lakhs. Separately, the company said it obtained a stay from the City Civil Court, Mumbai, against an order issued by the Estate Officer of the Mumbai Port Authority.

LTM Limited reported Q1 FY27 revenue of ₹11,608 crore, up 18% year on year, and net profit of ₹1,468.6 crore, up 17.1%. The company said its EBIT margin improved to 15.5%, an increase of 120 basis points from a year earlier. It also recorded a fair value gain of ₹1,978 million from the conversion of Voicing.AI convertible instruments into equity and disclosed a proposed acquisition of Randstad subsidiaries in Europe and Australia with an enterprise valuation of up to EUR 160 million, which has not yet closed. Cash and investments stood at ₹1,50,213 million.

Vikran Engineering’s board has approved providing corporate guarantees of up to ₹3,400 Crores and a promoter fund infusion of up to ₹1,160 Crores to its wholly owned subsidiaries to support operations and solar project financing. The arrangements are subject to bank credit approvals and will be treated as a contingent liability, with no immediate cash outflow or profit-and-loss impact expected. The company said the disclosures were made under SEBI’s listing regulations and that related-party transactions will be carried out on an arm’s-length basis.

Goodluck India’s board approved a 2:1 bonus issue of about 6,64,77,018 shares, revised its final dividend for the year ended March 31, 2026 to Re 1.00 per share, and cleared a ₹275 crore corporate guarantee for a subsidiary’s project loan. Its subsidiary Goodluck Defence and Aerospace Limited also secured a domestic order worth approximately Rs 255 crore for 155mm long range empty shells, with execution scheduled within 10 months. The developments represent material progress in operations and capital actions at the company level. They are expected to support the stock’s valuation and market sentiment.

Orchid Pharma’s merger scheme with Dhanuka Laboratories became effective on July 10, 2026, resulting in Dhanuka Laboratories being dissolved and all its assets, liabilities and business transferring to Orchid Pharma. Following the amalgamation, Orchid Pharma’s authorized share capital increased to ₹164,51,00,000 and the company set July 23 as the record date for issuing shares under a 161:5 exchange ratio (face value ₹10:₹100). Orchid Pharma also said it has signed an exclusive supply agreement with Russia’s Pharmasyntez for Exblifep, with a potential value of USD 178 million.